We observed substantial impairment in HRQL incomparison with the general population (SF-36, SF-6D,EQ-5D26) in both bridging fibrosis and cirrhosisgroups: P < .01 for PF, BP, GH, RE, and both utility scoresfor patients with bridging fibrosis and the same domainsplus RP and SF for patients with cirrhosis (P < .01)(Figure 1).